Program
sapanisertib
Also written as “Sapanisertib”, “MLN0128” and “TAK-128”.
Its studies are mostly in Breast Neoplasms · Endometrial Neoplasms · Diabetic Neuropathies · Carcinoma, Non-Small-Cell Lung · Clear-cell metastatic renal cell carcinoma, led by 3 companies.
Drug pageSapanisertib: every studyAll 47 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Takedaits history only | 80 open or running | phase 2since Sep 27, 2005 | Sep 27, 2005 | none ahead |
| Calithera Biosciencesits history only | 30 open or running | phase 2since Apr 28, 2016 | Jul 21, 2014 | none ahead |
| Faeth Therapeutics | 32 open or running | phase 2since Feb 7, 2022 | Feb 7, 2022 | Sep 2028phase 2 · NCT06463028 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Faeth Therapeutics only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 7, 2022First study: phase 2 study in Carcinoma, Non-Small-Cell LungFirst studyNCT05275673 · 7 enrolled · United States
- Jun 11, 2024Phase 2 study in Endometrial NeoplasmsNCT06463028 · 40 planned · United States
- Apr 17, 2026Phase 2 study in Breast NeoplasmsNCT07558733 · 32 planned · United States
Ahead
- Sep 2028Primary completion: phase 2 study in Endometrial NeoplasmsNCT06463028
- May 2029Primary completion: phase 2 study in Breast NeoplasmsNCT07558733
TargetBeta
“Serine/threonine-protein kinase mTOR inhibitor”ChEMBL 37, by rule
Other programs on MTOR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Sirolimus | Pfizer | phase 4 | 66 |
| gedatolisibrule | Pfizer | phase 3 | 9 |
| PI3K/mTOR Kinase Inhibitor WXFL10030390rule | shanghai-jiatan-pharmatech-co-ltd | phase 3 | 6 |
Studies
All 3 Faeth Therapeutics leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07558733Breast Neoplasms · United States | 2 | Recruiting | May 2029 | 32 |
| NCT06463028Endometrial Neoplasms · United States | 2 | Recruiting | Sep 2028 | 40 |
| NCT05275673Carcinoma, Non-Small-Cell Lung · United States | 2 | Terminated | Jan 24, 2023 | 7 |
How it is read
Names in the registry
- “Sapanisertib”, 5 entries
- “MLN0128”, 4 entries
- “TAK-128”, 4 entries
- “TAK-228”, 2 entries
- “sapanisertib”, 1 entry
Codes read as this program: TAK128.
Conditions, from the studies’ own filings
- Breast Neoplasms, 2 studies
- Endometrial Neoplasms, 2 studies
- Diabetic Neuropathies, 2 studies
- Carcinoma, Non-Small-Cell Lung, 1 study
- Clear-cell metastatic renal cell carcinoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.